AI-assisted research for pharma teams and investors, reviewed by experienced pharma professionals. We agree on the scope, deliverables, and timeline before work begins.
Research services
Launch planning
Research to support launch planning in each market.
The job
Launch plans depend on evidence from several markets and change as new data emerges. We bring that evidence together and can track developments as your plan evolves.
Example questions
- How could our product's positioning change as competitors enter the market over the next five years?
- Which patient groups are relevant to each treatment approach, and what factors affect treatment adoption?
- What messages are competitors using, and what evidence supports them?
Scope
Launch and brand strategy
Develop positioning recommendations for the next year, 2–3 years, and 3–5 years, taking current evidence and expected competition into account.
Monitored
Patient journey
Map the people, care settings, and barriers that shape diagnosis and treatment.
Point-in-time
Evidence gap analysis
Compare your evidence with competitor data to identify gaps and questions for clinical and commercial planning.
Point-in-time
What you get
- Evidence gaps relative to competitors' data packages
- Positioning options in a consistent format
- Competitor promotional materials and messaging changes
- Key opinion leader mapping and published views
- Analysis of competitor campaigns
- Evidence to inform your messaging
- Brand strategy recommendations
- Differences between markets
- Recommendations for the next year, 2–3 years, and 3–5 years
Turnaround
Typically 72–96 hours
Our review
- Market data is checked against sources for each geography.
- Messaging claims are reviewed against relevant regulatory guidance.
- Pharma professionals review the positioning recommendations.
Asset scouting and in-licensing
Find drug assets that fit your scientific and commercial criteria.
The job
Relevant assets may appear in trial registries, patent filings, company disclosures, or academic licensing records. We search across these sources and markets, including Chinese-language records, and flag gaps in the available information.
Example questions
- Identify Phase 2 oncology drug candidates in China that meet our scientific and licensing criteria.
- Find clinical-stage drug candidates targeting PTK7, with deal history and available patent information.
- Find gene therapy programs deprioritized in the past five years for reasons other than safety or efficacy, including licenses returned to academic institutions.
Scope
Asset scouting and in-licensing
Focused or broad searches by indication, target, stage, geography, and other agreed criteria.
Monitored
Asset prioritization
Rank assets against agreed criteria and explain the rationale.
Point-in-time
Market size
Estimate the addressable market, with sources and assumptions clearly stated.
Point-in-time
What you get
- A ranked table of identified assets and their latest reported status
- Profiles of shortlisted assets
- Comparable licensing and acquisition deals
- Available patent information for each asset
- Source references for the findings
Turnaround
24–48 hours
Our review
- Identified assets are checked against primary sources.
- Supporting sources and evidence gaps are recorded.
- Borderline matches are flagged for review.
- A pharma expert reviews the shortlist and exclusions.
Competitive intelligence
Understand the competitive landscape and track changes.
The job
Clinical results, regulatory decisions, and pipeline changes can affect your plans. We organize the available evidence and track developments relevant to your assets and markets.
Example questions
- Compare GLP-1 programs by development stage, trial design, and upcoming milestones.
- How might the VAV1 competitive landscape change over the next three years?
- Map ADPKD assets from preclinical development through launch.
Scope
Competitive analysis
Map the current pipeline and profile assets relevant to your question.
Monitored
Emerging approaches and competitors
New therapeutic approaches and emerging players
Monitored
Future unmet needs
Assess how current unmet needs could change as investigational therapies progress.
Monitored
What you get
- Identified competitors, pipeline status, positioning, and stated differentiation
- Available preclinical and clinical evidence
- Expected milestones and data readouts, with dates and sources
- Current unmet needs and how they may change
- A landscape updated on an agreed schedule, with alerts for relevant changes
Turnaround
Typically 48–72 hours for the initial report; monitoring follows an agreed schedule.
Our review
- Competitors are cross-checked across registries and company disclosures.
- Direct quotations are distinguished from our analysis.
- A pharma expert reviews the competitor list for potential gaps.
Due diligence
Company and asset assessments for investment, licensing, and acquisition decisions.
The job
Before a deal, you need a clear view of the evidence, risks, and open questions. We review clinical data, patent information, competitors, and company background to answer the questions defined in the project scope.
Example questions
- Evaluate a clinical-stage company developing CD19-targeted therapies for autoimmune indications.
- Identify key risks and open questions for a company with a Phase 2 asset.
Scope
Company & asset diligence
An assessment of the asset, company, evidence, and competitive context.
Point-in-time
IP & patent landscape
Patent coverage, exclusivity, and questions for freedom-to-operate review.
Point-in-time
Deal comparables
Relevant transactions to inform valuation discussions.
Point-in-time
Target product profile benchmarking
Compare the proposed product profile with current and expected competitors.
Point-in-time
What you get
- A memo summarizing key risks and open questions
- An assessment against agreed criteria, including clinical evidence and funding runway
- A competitive benchmarking table
- Epidemiology and addressable market estimates, with assumptions
- A patent landscape brief and questions for legal review
- Comparable transactions and relevant deal terms
Turnaround
Typically 24–48 hours
Our review
- Key risks are linked to supporting documents.
- Clinical results are checked against available primary sources.
- Available regulatory history and development plans are reviewed.
- A pharma expert reviews the final assessment.
Custom research
Research scoped around your question.
The job
Some questions span several services or require a different approach. We can scope a project around the decision you need to make, the evidence available, and your deadline.
Example questions
- Identify priority treatment centers in the US for our approved therapy, with patient population estimates, relevant clinicians, and a recommended outreach sequence.
- Map cardiovascular disease burden by city and review evidence for relevant interventions.
- Compare therapies across five regulatory regions by care setting, supply coverage, and price range.
- Which accelerated-approval pathways fit this asset, and who reached market that way?
- Identify academic drug development programs with promising research that stalled because of funding or strategic decisions.
- Assess our commercial team's readiness to adopt AI.
Where we've already worked
Site of care and field strategy
Treatment centers ranked by estimated patient population, with relevant clinicians, potential research partners, and a proposed outreach sequence.
Population health and burden of disease
City-level cardiovascular disease estimates and country-level forecasts of patient numbers and disability-adjusted life years (DALYs).
Pricing, supply and access across geographies
A comparison of therapies across five regulatory regions, covering manufacturers, supply coverage, care settings, and price ranges.
Regulatory pathway strategy
An assessment of relevant accelerated approval pathways, with examples of drugs approved through them.
Technology and platform landscapes
A map of companies developing a selected technology or modality, organized by therapeutic area.
Deprioritized drug development programs
A review of clinical-stage and academic drug development programs discontinued for funding, licensing, or strategic reasons, based on the explanations available in published sources.
Discontinued drug programs
A review of discontinued drug assets, including their current ownership and licensing history, based on company disclosures and academic licensing records.
Organizational readiness
A review of your commercial team's data, workflows, and capabilities to identify where AI could be useful and what implementation would require.
What you get
- A deliverable with an agreed scope, format, and review process.
Turnaround
Timeline agreed during scoping
We'll confirm the approach, deliverables, and delivery date before work begins.
Our review
- The research approach is reviewed before work begins.
- Sources and evidence gaps are documented.
- A pharma expert reviews the final deliverable.